1248 | Humans |
622 | Influenza, Human (epidemiology) |
577 | Female |
513 | Male |
503 | Influenza, Human (prevention & control) |
468 | Adult |
425 | Middle Aged |
397 | Canada |
395 | Aged |
374 | Canada (epidemiology) |
355 | Adolescent |
334 | Child |
281 | Child, Preschool |
235 | Infant |
234 | Influenza Vaccines (administration & dosage) |
214 | Young Adult |
208 | Influenza, Human (virology) |
206 | Animals |
174 | Disease Outbreaks |
165 | Ontario (epidemiology) |
164 | Influenza A Virus, H1N1 Subtype |
154 | Aged, 80 and over |
152 | Seasons |
137 | Ontario |
114 | Risk Factors |
110 | Infant, Newborn |
108 | Influenza Vaccines (immunology) |
108 | Disease Outbreaks (prevention & control) |
99 | Influenza A virus (isolation & purification) |
93 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
90 | Influenza Vaccines (adverse effects) |
89 | Vaccination (statistics & numerical data) |
88 | Retrospective Studies |
88 | Incidence |
86 | Surveys and Questionnaires |
86 | Pandemics |
83 | Influenza, Human (diagnosis) |
80 | Influenza Vaccines (therapeutic use) |
80 | Influenza A Virus, H1N1 Subtype (immunology) |
78 | Influenza, Human (immunology) |
73 | Influenza Vaccines |
70 | Population Surveillance |
70 | Antiviral Agents (therapeutic use) |
70 | Age Factors |
68 | Time Factors |
68 | Hospitalization (statistics & numerical data) |
66 | Pregnancy |
63 | Vaccination |
63 | United States |
63 | Influenza, Human (transmission) |
63 | Influenza, Human (drug therapy) |
58 | Cross-Sectional Studies |
56 | Influenza, Human (mortality) |
55 | Influenza in Birds (epidemiology) |
54 | Orthomyxoviridae Infections (veterinary) |
53 | Prospective Studies |
53 | Influenza A virus (immunology) |
52 | Phylogeny |
51 | Health Knowledge, Attitudes, Practice |
50 | Swine |
50 | Alberta |
49 | Influenza, Human (therapy) |
48 | Quebec |
48 | Pandemics (prevention & control) |
48 | Influenza A virus |
45 | Treatment Outcome |
45 | Quebec (epidemiology) |
45 | Influenza, Human (complications) |
45 | Influenza B virus (isolation & purification) |
45 | Cohort Studies |
44 | Influenza in Birds (virology) |
44 | Case-Control Studies |
43 | Hemagglutination Inhibition Tests |
43 | Antibodies, Viral (blood) |
42 | Sentinel Surveillance |
42 | Prevalence |
42 | Influenza A virus (genetics) |
41 | Population Surveillance (methods) |
41 | Influenza A virus (classification) |
40 | Orthomyxoviridae Infections (epidemiology) |
39 | Age Distribution |
38 | Hospitalization |
38 | Disease Outbreaks (veterinary) |
37 | Risk Assessment |
37 | Respiratory Tract Infections (epidemiology) |
35 | Molecular Sequence Data |
35 | Logistic Models |
35 | Attitude of Health Personnel |
34 | Sequence Analysis, DNA |
33 | Manitoba (epidemiology) |
33 | Immunization Programs |
33 | Alberta (epidemiology) |
32 | Orthomyxoviridae Infections (virology) |
32 | Influenza A Virus, H1N1 Subtype (genetics) |
32 | Health Personnel |
31 | Swine Diseases (virology) |
31 | Public Health |
31 | British Columbia |
31 | British Columbia (epidemiology) |
30 | United States (epidemiology) |
30 | History, 20th Century |
29 | Orthomyxoviridae (isolation & purification) |
29 | Immunization Programs (statistics & numerical data) |
28 | Swine Diseases (epidemiology) |
28 | Influenza B virus (immunology) |
28 | Amantadine (therapeutic use) |
27 | Risk |
27 | Respiratory Tract Infections (virology) |
27 | Influenza, Human (history) |
27 | Influenza A Virus, H3N2 Subtype (isolation & purification) |
27 | Comorbidity |
26 | Socioeconomic Factors |
26 | Models, Theoretical |
26 | Influenza B virus |
25 | RNA, Viral (genetics) |
25 | Influenza A Virus, H3N2 Subtype |
25 | Health Policy |
25 | Cost-Benefit Analysis |
25 | Birds |
24 | Influenza Vaccines (supply & distribution) |
24 | Influenza Vaccines (economics) |
23 | Sensitivity and Specificity |
23 | Long-Term Care |
23 | Influenza A virus (pathogenicity) |
23 | Influenza A Virus, H3N2 Subtype (immunology) |
23 | Emergency Service, Hospital (statistics & numerical data) |
22 | Vaccination (methods) |
21 | Severity of Illness Index |
21 | Practice Guidelines as Topic |
21 | Manitoba |
20 | Reverse Transcriptase Polymerase Chain Reaction |
20 | Qualitative Research |
20 | Pandemics (statistics & numerical data) |
20 | Nursing Homes |
20 | Models, Statistical |
20 | Influenza, Human (microbiology) |
20 | Influenza A Virus, H3N2 Subtype (genetics) |
20 | Disease Outbreaks (statistics & numerical data) |
20 | Disaster Planning (organization & administration) |
20 | Cross Infection (prevention & control) |
19 | Sex Factors |
19 | Severe Acute Respiratory Syndrome (epidemiology) |
19 | Odds Ratio |
19 | Influenza in Birds (transmission) |
19 | Infection Control (methods) |
19 | Cross Infection (epidemiology) |
18 | Oseltamivir (therapeutic use) |
18 | Immunization Programs (organization & administration) |
18 | Decision Making |
18 | Attitude to Health |
17 | Vaccines, Inactivated (immunology) |
17 | Seroepidemiologic Studies |
17 | Respiratory Tract Diseases (epidemiology) |
17 | Reproducibility of Results |
17 | Program Evaluation |
17 | Outcome Assessment, Health Care |
17 | Interviews as Topic |
17 | Influenza, Human |
17 | Influenza, Human (economics) |
17 | Immunization Schedule |
17 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
17 | Health Surveys |
17 | Health Care Surveys |
17 | Disease Outbreaks (history) |
17 | Absenteeism |
16 | Travel |
16 | Rural Population |
16 | Pregnancy Complications, Infectious (prevention & control) |
16 | Pilot Projects |
16 | Patient Acceptance of Health Care |
16 | National Health Programs |
16 | Multivariate Analysis |
16 | Influenza B virus (genetics) |
16 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
16 | Europe |
16 | Data Collection |
16 | Computer Simulation |
15 | Viral Proteins (genetics) |
15 | Vaccines, Inactivated (administration & dosage) |
15 | Vaccination (standards) |
15 | Vaccination (psychology) |
15 | Pneumococcal Infections (prevention & control) |
15 | Orthomyxoviridae (immunology) |
15 | Models, Biological |
15 | Influenza, Human (ethnology) |
15 | Influenza in Birds (prevention & control) |
15 | Immunization |
15 | Follow-Up Studies |
15 | Europe (epidemiology) |
15 | Epidemiological Monitoring |
15 | Epidemics |
15 | Drug Resistance, Viral |
15 | Disaster Planning |
14 | Poultry Diseases (epidemiology) |
14 | Pneumonia (epidemiology) |
14 | Neuraminidase (genetics) |
14 | Intensive Care Units |
14 | Health Behavior |
14 | Adjuvants, Immunologic (administration & dosage) |
13 | Urban Population |
13 | Syndrome |
13 | Respiratory Tract Diseases (etiology) |
13 | Pregnancy Complications, Infectious (epidemiology) |
13 | Patient Compliance |
13 | Internet |
13 | Influenza, Human (pathology) |
13 | Indians, North American (statistics & numerical data) |
13 | Immunization Programs (standards) |
13 | Immunization (statistics & numerical data) |
13 | Horses |
13 | Health Planning |
13 | Databases, Factual |
13 | Communicable Diseases (epidemiology) |
13 | Communicable Disease Control (methods) |
13 | Acute Disease |
12 | United Kingdom |
12 | Registries |
12 | Poultry |
12 | Orthomyxoviridae Infections (transmission) |
12 | Orthomyxoviridae (classification) |
12 | Nova Scotia |
12 | Neutralization Tests |
12 | Nasopharynx (virology) |
12 | Influenza B virus (classification) |
12 | Influenza A Virus, H1N1 Subtype (classification) |
12 | Health Status |
12 | Health Services Accessibility |
12 | Focus Groups |
12 | Community-Acquired Infections (epidemiology) |
12 | Antigens, Viral (immunology) |
12 | Antigens, Viral (analysis) |
12 | Animals, Wild (virology) |
11 | Workforce |
11 | Vaccination (adverse effects) |
11 | Turkeys |
11 | Species Specificity |
11 | Schools |
11 | Public Health Administration |
11 | Poultry Diseases (virology) |
11 | Oseltamivir |
11 | Orthomyxoviridae |
11 | Linear Models |
11 | Length of Stay |
11 | Influenza A Virus, H5N1 Subtype |
11 | Health Personnel (psychology) |
11 | Genotype |
11 | Cluster Analysis |
11 | Chronic Disease |
11 | Base Sequence |
11 | Antiviral Agents (administration & dosage) |
11 | Animals, Wild |
10 | Virus Diseases (virology) |
10 | Virus Diseases (epidemiology) |
10 | Sex Distribution |
10 | Severe Acute Respiratory Syndrome (prevention & control) |
10 | Respiratory Tract Infections (veterinary) |
10 | Respiratory Tract Infections (diagnosis) |
10 | Residence Characteristics |
10 | Regression Analysis |
10 | Public Opinion |
10 | Polymerase Chain Reaction |
10 | Patient Selection |
10 | Patient Acceptance of Health Care (statistics & numerical data) |
10 | Nova Scotia (epidemiology) |
10 | Mutation |
10 | Longitudinal Studies |
10 | Influenza, Human (psychology) |
10 | Influenza A Virus, H5N1 Subtype (genetics) |
10 | Influenza A Virus, H1N1 Subtype (drug effects) |
10 | Indians, North American |
10 | History, 21st Century |
10 | Health Personnel (statistics & numerical data) |
10 | Global Health |
10 | Family Practice |
10 | Eye Diseases (etiology) |
10 | Emergency Service, Hospital |
10 | Ducks (virology) |
10 | Contraindications |
10 | Confidence Intervals |
10 | Communication |
10 | Birds (virology) |
10 | Antiviral Agents (pharmacology) |
10 | Antibodies, Viral (analysis) |
10 | Anti-Bacterial Agents (therapeutic use) |
10 | Amino Acid Sequence |
9 | Virulence |
9 | Vaccines, Inactivated (adverse effects) |
9 | Vaccination (economics) |
9 | Reassortant Viruses (genetics) |
9 | Public Health Practice |
9 | Pneumonia, Viral (epidemiology) |
9 | Pneumonia (mortality) |
9 | Intensive Care Units (statistics & numerical data) |
9 | Influenza, Human (etiology) |
9 | Influenza Vaccines (standards) |
9 | Immunization Programs (economics) |
9 | Horse Diseases (epidemiology) |
9 | Health Services Research |
9 | Genome, Viral |
9 | Data Collection (methods) |
9 | Critical Illness |
9 | Complement Fixation Tests |
9 | Communicable Disease Control |
9 | Clinical Trials as Topic |
9 | Animal Migration |
9 | Algorithms |
8 | Zanamivir |
8 | Serologic Tests |
8 | Saskatchewan (epidemiology) |
8 | Pyrans |
8 | Prognosis |
8 | Pregnancy Complications, Infectious (virology) |
8 | Patient Education as Topic |
8 | Patient Admission |
8 | Patient Admission (statistics & numerical data) |
8 | Organizational Policy |
8 | Newfoundland and Labrador (epidemiology) |
8 | Neuraminidase (antagonists & inhibitors) |
8 | Mortality |
8 | Mice |
8 | Information Dissemination |
8 | Influenza, Human (physiopathology) |
8 | Influenza A Virus, H3N2 Subtype (classification) |
8 | Hospitalization (trends) |
8 | Health Services Needs and Demand |
8 | Guanidines |
8 | Genes, Viral |
8 | Family Characteristics |
8 | Evidence-Based Medicine |
8 | Electronic Health Records |
8 | Disease Outbreaks (economics) |
8 | Costs and Cost Analysis |
8 | Cooperative Behavior |
8 | Chickens |
8 | Cell Line |
8 | Antiviral Agents (adverse effects) |
8 | Antibodies, Viral (immunology) |
7 | World Health Organization |
7 | Viruses (isolation & purification) |
7 | Swine Diseases (transmission) |
7 | Survival Analysis |
7 | Sialic Acids (therapeutic use) |
7 | Serotyping |
7 | Sentinel Surveillance (veterinary) |
7 | Respiratory Syncytial Virus Infections (epidemiology) |
7 | Randomized Controlled Trials as Topic |
7 | Primary Health Care |
7 | Pregnancy Outcome |
7 | Predictive Value of Tests |
7 | Practice Patterns, Physicians' (statistics & numerical data) |
7 | Poultry (virology) |
7 | Pneumonia, Pneumococcal (prevention & control) |
7 | Pneumococcal Vaccines (administration & dosage) |
7 | Pneumococcal Infections (epidemiology) |
7 | Office Visits (statistics & numerical data) |
7 | Nurse's Role |
7 | Needs Assessment |
7 | Mutation, Missense |
7 | Military Personnel |
7 | Mass Vaccination (statistics & numerical data) |
7 | International Cooperation |
7 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
7 | Influenza A Virus, H1N1 Subtype (physiology) |
7 | Infection Control (organization & administration) |
7 | Hospitals, Pediatric |
7 | Hospitals (statistics & numerical data) |
7 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
7 | Health Promotion |
7 | Genetic Variation |
7 | Evolution, Molecular |
7 | Ducks (microbiology) |
7 | Drug Utilization |
7 | Drug Combinations |
7 | Disease Transmission, Infectious (prevention & control) |
7 | Demography |
7 | Critical Care |
7 | Cost of Illness |
7 | Clinical Laboratory Techniques |
7 | Chickens (virology) |
7 | Asthma (epidemiology) |
7 | Antiviral Agents (supply & distribution) |
7 | Analysis of Variance |
7 | Alaska (epidemiology) |
7 | Acetamides (therapeutic use) |
6 | Zoonoses |
6 | Yukon Territory (epidemiology) |
6 | World War I |
6 | Urban Health |
6 | Universities |
6 | Telephone |
6 | Squalene (administration & dosage) |
6 | Safety |
6 | Risk Assessment (methods) |
6 | Respiratory Tract Infections (prevention & control) |
6 | Respiratory Tract Infections (microbiology) |
6 | Respiratory Tract Infections (drug therapy) |
6 | Respiration, Artificial |
6 | Reassortant Viruses (isolation & purification) |
6 | Real-Time Polymerase Chain Reaction |
6 | Quality of Life |
6 | Public Health Surveillance (methods) |
6 | Public Health (methods) |
6 | Preventive Health Services (statistics & numerical data) |
6 | Polysorbates (administration & dosage) |
6 | Policy Making |
6 | Pneumonia, Viral (veterinary) |
6 | Pneumonia, Pneumococcal (epidemiology) |
6 | Physicians |
6 | Oseltamivir (administration & dosage) |
6 | Neuraminidase (immunology) |
6 | Models, Economic |
6 | Masks |
6 | Influenza A virus (physiology) |
6 | Influenza A Virus, H5N2 Subtype (isolation & purification) |
6 | Influenza A Virus, H5N1 Subtype (isolation & purification) |
6 | Hospitals |
6 | Homes for the Aged |
6 | History, 19th Century |
6 | Health Facilities |
6 | Guidelines as Topic |
6 | Geography |
6 | Family Practice (statistics & numerical data) |
6 | Eye Diseases (epidemiology) |
6 | Emergency Service, Hospital (organization & administration) |
6 | Drug-Related Side Effects and Adverse Reactions (epidemiology) |
6 | Dogs |
6 | Disease Reservoirs |
6 | Disease Reservoirs (veterinary) |
6 | Disease Outbreaks (epidemiology) |
6 | Communicable Diseases, Emerging (epidemiology) |
6 | Australia |
6 | Asthma (complications) |
6 | Antiviral Agents (economics) |
6 | Antigens, Viral (genetics) |
6 | Antigenic Variation |
6 | Aging |
6 | Advisory Committees |
6 | Adjuvants, Immunologic (adverse effects) |
5 | alpha-Tocopherol (administration & dosage) |
5 | Zanamivir (therapeutic use) |
5 | Viral Load |
5 | Turkeys (virology) |
5 | Triage |
5 | Triage (methods) |
5 | Temperature |
5 | Swine Diseases (microbiology) |
5 | Swine Diseases (immunology) |
5 | Swine (virology) |
5 | Streptococcus pneumoniae (isolation & purification) |
5 | Social Class |
5 | Skilled Nursing Facilities |
5 | Sequence Homology |
5 | Self Report |
5 | Self Care (methods) |
5 | Rhinovirus (isolation & purification) |
5 | Respiratory Tract Infections |
5 | Respiratory Tract Infections (mortality) |
5 | Respiratory Tract Infections (etiology) |
5 | Residence Characteristics (statistics & numerical data) |
5 | Research Design |
5 | Recurrence |
5 | Reassortant Viruses |
5 | Public Health Surveillance |
5 | Public Health Administration (methods) |
5 | Primary Health Care (statistics & numerical data) |
5 | Premature Birth (epidemiology) |
5 | Practice Patterns, Physicians' |
5 | Population Density |
5 | Poisson Distribution |
5 | Pneumonia, Viral (virology) |
5 | Pneumococcal Vaccines |
5 | Physicians, Family |
5 | Paramyxoviridae Infections |
5 | Paramyxoviridae Infections (virology) |
5 | Paramyxoviridae Infections (epidemiology) |
5 | Orthomyxoviridae Infections (microbiology) |
5 | Orthomyxoviridae Infections (immunology) |
5 | Orthomyxoviridae Infections (diagnosis) |
5 | Orthomyxoviridae (genetics) |
5 | Organizational Case Studies |
5 | Nose (virology) |
5 | Motivation |
5 | Military Medicine |
5 | Microbial Sensitivity Tests |
5 | Mexico (epidemiology) |
5 | Mass Vaccination |
5 | Mass Screening |
5 | Mass Media |
5 | Mandatory Programs |
5 | Lung (pathology) |
5 | Laboratories |
5 | Influenza, Human (classification) |
5 | Influenza Vaccines (pharmacology) |
5 | Influenza B virus (drug effects) |
5 | Influenza A Virus, H5N2 Subtype (pathogenicity) |
5 | Influenza A Virus, H5N2 Subtype (genetics) |
5 | Influenza A Virus, H3N2 Subtype (pathogenicity) |
5 | Infectious Disease Transmission, Professional-to-Patient (prevention & control) |
5 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
5 | Infection Control |